Dr Anki Malmborg-Hager
SenzaGen AB, Medicon Village, Scheelev. 2, 223 81 Lund, Sweden
Tel: +46 46 2756200 office / +46 708 204481 sales
Email: email@example.com / firstname.lastname@example.org
SenzaGen markets, sells and performs the in vitro GARDskin (Genomic Allergen Rapid Detection) genome based sensitisation test for skin sensitisation and potency classification according to the CLP standard, GARDpotency. GARD TM is the new test that, with higher accuracy than any other available test methods, reveals whether chemical substances are at risk of causing allergies in humans. A novel test for respiratory sensitisation is also under development, GARDair. As a quality-orientated and innovative international player, SenzaGen supports its clients with stringent quality assessments, recommended by ECHA and undergoes ECVAM and OECD validation. The GARD test is available through licence in international laboratories and sold through distributors in EU and Asia.
Click on profile to view in full screen. Click on print icon to print profile. Alternatively, download the pdf of the full 2017 guide